Method for detecting the related substance 2-sulfotryptophan in compound amino acid injection

The detection of 2-sulfotopyptophan in compound amino acid injections was solved by high-performance liquid chromatography, and the problem of impurity detection in compound amino acid injections was solved, achieving effective control of product quality and safety guarantee.

CN112697930BActive Publication Date: 2024-12-06BEIJING INST OF DRUG INSPECTION (BEIJING VACCINE INSPECTION CENT)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110095332.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-01-25
Publication Date
2024-12-06
Estimated Expiration
2041-01-25

AI Technical Summary

Technical Problem

There are unknown impurities in existing compound amino acid injections, especially those related to tryptophan, which are difficult to detect and track, affecting product quality and safety.

Method used

Using high-performance liquid chromatography, using octadecylsilane bonded silica gel as filler, combined with ammonium sulfate buffer and acetonitrile as mobile phase, the compound amino acid injection was determined by gradient elution and quantitative dilution of the reference solution. 2-Sulfotryptophan content ensures the accuracy and sensitivity of detection.

Benefits of technology

It realizes rapid and accurate detection of 2-sulfotopyptophan in compound amino acid injection, ensures product quality control and safety, provides a fast, simple, sensitive and stable method, which can be 0.02μg/ml The impurity content is effectively detected within the detection limit.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure GHA0000008009880000031
    Figure GHA0000008009880000031
  • Figure GHA0000008009880000071
    Figure GHA0000008009880000071
Patent Text Reader

Abstract

The present invention discloses a method for detecting a related substance 2-sulfotryptophan in a compound amino acid injection. On the one hand, the present invention relates to a compound shown in formula I. On the other hand, the present invention also relates to the use of a compound of formula I in the inspection of related substances in a compound amino acid injection, wherein the compound amino acid injection comprises tryptophan and sodium bisulfite or sodium pyrosulfite; for example, the compound amino acid injection is selected from: compound amino acid (15) dipeptide (2) injection, compound amino acid injection (18AA), compound amino acid injection (18AA-I), compound amino acid injection (18AA-II), and compound amino acid injection (18AA-III). Another aspect relates to a method for inspecting related substances in a compound amino acid injection, wherein the method uses high performance liquid chromatography to measure the content of the impurity 2-sulfotryptophan in the injection. The method of the present invention can quickly and accurately measure the content of related impurities in these injections.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and relates to a method for detecting a compound amino acid injection, and in particular to a method for detecting a related substance 2-sulfotryptophan in the compound amino acid injection. The method of the present invention presents the excellent technical effect as described in the present invention. Background Art

[0002] Compound amino acid injection is a sterile aqueous solution made of a variety of amino acids. It is mainly used for patients who cannot take nutrients orally or through the intestines or whose nutrition cannot meet their needs. This product is infused intravenously to meet the body's needs for amino acid synthesis of proteins. In addition to the amino acid components, a certain concentration of sodium bisulfite or sodium metabisulfite is added to the product prescription as an antioxidant to inhibit the production of impurities due to oxidation reactions of some easily oxidized amino acids in the product.

[0003] Unfortunately, however, it has been found that some compound amino acid injections contain an unknown impurity that is typical and possibly related to tryptophan. Tracing the source of this impurity and effectively detecting it are what those skilled in the art are eagerly looking forward to. Summary of the invention

[0004] The object of the present invention is to provide a method for detecting related substances in a compound amino acid injection, and also to relate to impurity compounds used for detection by the method. It has been unexpectedly found that the method of the present invention can effectively detect impurities related to tryptophan in the compound amino acid injection. The present invention is completed based on such a discovery.

[0005] To this end, the first aspect of the present invention provides the use of the following compound of formula I in the inspection of related substances in compound amino acid injection:

[0006] The compound of formula I may also be referred to as 2-sulfotryptophan.

[0007] According to the use of the first aspect of the present invention, the compound amino acid injection contains tryptophan and sodium bisulfite or sodium pyrosulfite.

[0008] According to the use of the first aspect of the present invention, the compound amino acid injection is selected from: compound amino acid (15) dipeptide (2) injection, compound amino acid injection (18AA), compound amino acid injection (18AA-I), compound amino acid injection (18AA-II), and compound amino acid injection (18AA-III). These amino acid injections have been included in the Chinese Pharmacopoeia. For example, the above five injections have been recorded in the 2020 edition of the Pharmacopoeia of the People's Republic of China, Part II, pages 977, 978, 979, 981, and 982; in the context of the present invention, unless otherwise specified, the various injections mentioned above refer to commercially available samples of the variety. If it is specifically specified that it is a homemade sample, it is prepared according to the above pharmacopoeia formula; wherein the compound amino acid injection (18AA) is a product with a concentration of 12%, and the compound amino acid injection (18AA-II) is a product with a concentration of 5%. Typically, these compound amino acid injections contain tryptophan and sodium bisulfite or sodium pyrosulfite.

[0009] Furthermore, the second aspect of the present invention relates to a method for examining related substances in a compound amino acid injection, wherein the method uses high performance liquid chromatography to determine the content of the impurity 2-sulfotryptophan in the injection.

[0010] According to the method of the second aspect of the present invention, the high performance liquid chromatography is performed in accordance with the specifications in General Rules 0512 of Part Four of the 2020 Edition of the Chinese Pharmacopoeia.

[0011] The method according to the second aspect of the present invention comprises the following operations:

[0012] It is carried out according to the specifications of high performance liquid chromatography in the general rules 0512 of the fourth volume of the 2020 edition of the Chinese Pharmacopoeia;

[0013] Chromatographic conditions: octadecylsilane bonded silica gel was used as filler, ammonium sulfate buffer (5 g ammonium sulfate, 5.25 g sodium heptane sulfonate, dissolved in 900 ml water, adjusted to pH 1.5 with hydrochloric acid, and added with water to 1000 ml)-acetonitrile (97:3) was used as mobile phase A, acetonitrile was used as mobile phase B, gradient elution was performed according to the table below, injection volume was 25 μl, column temperature was 40°C, and detection wavelength was 220 nm;

[0014] time B% 0 0 18 0 27 45 32 0 53 0

[0015] Reference solution: accurately weigh an appropriate amount of 2-sulfotryptophan reference substance, dissolve it in water and quantitatively dilute it to make a solution with a concentration of 0.05-0.2 μg / ml as the reference solution; (the concentration of the reference solution can be appropriately adjusted according to the impurity 2-sulfotryptophan in different test samples, so that the concentration of the reference solution is within a comparable concentration range with the concentration of the impurity in the test solution); Test solution: accurately measure 2.5 ml of compound amino acid injection solution and place it in a 5 ml volumetric flask, accurately add 0.2 ml of ethylenediamine and 2 ml of acetone, mix well, add acetone to the scale, and vortex. After mixing for 15 minutes, filter, accurately measure 2 ml of the filtrate, place it in a 10 ml volumetric flask, and dilute it to the mark with ultrapure water as the test solution; System suitability test: add an appropriate amount of reference substance to the compound amino acid injection to a concentration of 1 μg / ml to obtain a system suitability test solution, inject the reference substance solution and the system suitability test solution into a liquid chromatograph, respectively, and determine the retention time of 2-sulfotryptophan through the chromatogram of the reference substance solution. The separation between 2-sulfotryptophan and its adjacent chromatographic peaks in the chromatogram of the system suitability test solution should be greater than 5.0;

[0016] Determination method: Accurately measure the test solution and the reference solution, inject them into the chromatograph respectively, record the chromatogram, calculate the content of the impurity 2-sulfotryptophan in the test solution by the peak area according to the external standard method, and calculate the content of the impurity 2-sulfotryptophan in the compound amino acid injection according to the dilution multiple of the prepared solution.

[0017] According to the method of the second aspect of the present invention, the specification of the chromatographic column using octadecylsilane bonded silica gel as a filler is 4.6×150 mm, 3.5 μm.

[0018] According to the method of the second aspect of the present invention, the correlation coefficient of the linear equation of 2-sulfotryptophan in the concentration range of 0.05 μg / ml to 2.0 μg / ml is r>0.999.

[0019] According to the method of the second aspect of the present invention, the method recovery rate of 2-sulfotryptophan is greater than 95%, especially greater than 98%, for example, between 98% and 102.

[0020] According to the method of the second aspect of the present invention, the detection limit of 2-sulfotryptophan is less than 0.02 μg / ml, such as less than 0.015 μg / ml.

[0021] According to the method of the second aspect of the present invention, the RSD of the 2-sulfotryptophan content determination result of the prepared test solution at room temperature within the range of 0 to 24 hours is less than 1%, especially less than 0.5%, especially less than 0.2%.

[0022] According to the method of the second aspect of the present invention, the compound amino acid injection contains tryptophan and sodium bisulfite or sodium pyrosulfite.

[0023] According to the method of the second aspect of the present invention, the compound amino acid injection is selected from: compound amino acid (15) dipeptide (2) injection, compound amino acid injection (18AA), compound amino acid injection (18AA-I), compound amino acid injection (18AA-II), and compound amino acid injection (18AA-III).

[0024] Furthermore, the third aspect of the present invention provides a compound having a chemical structure as shown in Formula I below:

[0025]

[0026] In the method steps described in the present application, although the specific steps described therein are different from the steps described in the preparation examples in the specific implementation section below in some details or language descriptions, those skilled in the art can fully summarize the above-described method steps based on the detailed disclosure of the entire text of the present application.

[0027] Any embodiment of any aspect of the present application can be combined with other embodiments, as long as they do not conflict. In addition, in any embodiment of any aspect of the present application, any technical feature can be applied to the technical features in other embodiments, as long as they do not conflict.

[0028] The application is further described below. All documents cited in the application are incorporated herein by reference in their entirety, and if the meanings expressed in these documents are inconsistent with the application, the description of the application shall prevail. In addition, the various terms and phrases used in the application have the general meanings known to those skilled in the art, even so, the application still hopes to make more detailed descriptions and explanations of these terms and phrases here, and the terms and phrases mentioned, if inconsistent with the known meanings, shall prevail with the meanings described in the application.

[0029] There is a document (Gao Chun, et al., Electronic Journal of Tumor Metabolism and Nutrition, 2019-02) that details the precautions for compound amino acid injection and its clinical application. For example, amino acids are the basic substances that constitute the proteins required for human nutrition, and are also the precursors of the body's synthesis of antibodies, hormones, enzymes and other molecules. They participate in a series of metabolic reactions in the body and can be converted into carbohydrates and fats, and finally metabolized into carbon dioxide, water and urea to produce energy. They are one of the three major macronutrients for nutritional therapy. The proteins that make up the human body are composed of 20 amino acids, of which 8 amino acids cannot be synthesized by the human body itself and must be supplemented from exogenous sources. They are called essential amino acids (EAA). Amino acids that can be synthesized from precursor substances in the human body and do not need to be obtained from food are called non-essential amino acids (NEAA). In addition, although some amino acids can be synthesized by the human body, they cannot meet normal needs under special circumstances. They are called semi-essential amino acids or conditionally essential amino acids (CEAA). For example, for infants in the growth and development period, histidine is an essential amino acid; tyrosine is an essential amino acid for premature infants, and cysteine ​​is an essential amino acid for premature infants and full-term infants; for patients with kidney disease, tyrosine is an essential amino acid; for patients with liver disease, cysteine ​​is an essential amino acid. This classification method is only based on whether it can be synthesized in the body, not on nutritional value. In terms of completing metabolic functions, all amino acids are needed, and each amino acid has its specific physiological function. Amino acids are divided into aromatic amino acids, aliphatic amino acids and heterocyclic amino acids according to their side chain structure. Aromatic amino acids include phenylalanine, tryptophan and tyrosine. Among aliphatic amino acids, the side chains of leucine, isoleucine and valine are only hydrocarbon chains, and they have branches, so they are called branched-chain amino acids (BCAA). It is worth noting that to ensure the full utilization of amino acids, sufficient non-protein calories (NPC) must be provided, that is, the calories provided by glucose and fat (1g glucose can provide about 4kcal calories, 1g fat can provide about 9kcal calories), otherwise the supplemented amino acids will be consumed as calories. The heat-nitrogen ratio of most patients with stable conditions is 150kcal:1g nitrogen, and this ratio is 100-150kcal:1g nitrogen for perioperative patients. The nitrogen content can be calculated by the formula "nitrogen content (g) = amino acid content (g) × 16%". The emergence of compound amino acid injection makes intravenous amino acid supplementation possible. At present, there are more than 20 types of compound amino acid injections approved for marketing by the State Food and Drug Administration. Compound amino acid injections are mainly divided into balanced amino acid injections and disease-appropriate amino acid injections, and their amino acid concentrations range from 3% to 15%.Balanced compound amino acid injections are based on the amino acid ratios of human milk, milk, potatoes, etc. Common ones include compound amino acid injection (18AA), compound amino acid injection (18AA-Ⅰ), compound amino acid injection (18AA-Ⅱ), compound amino acid injection (18AA-Ⅲ), compound amino acid injection (18AA-Ⅳ), compound amino acid injection (18AA-Ⅴ), compound amino acid injection (14AA), compound amino acid injection (17AA), etc. Disease-applicable compound amino acid injections are based on the amino acid metabolism characteristics of different diseases, including liver disease-applicable type, kidney disease-applicable type and trauma-applicable type. Liver disease-applicable types include compound amino acid injection (3AA), compound amino acid injection (6AA), compound amino acid injection (17AA-Ⅲ) and compound amino acid injection (20AA), etc. Kidney disease-applicable types include compound amino acid injection (9AA) and compound amino acid injection (18AA-Ⅸ), etc. The trauma-applicable types include compound amino acid injection (15-HBC) and compound amino acid injection (18AA-VII). In addition, there are compound amino acid injections for children, such as pediatric compound amino acid injection (18AA-I), pediatric compound amino acid injection (18AA-II) and pediatric compound amino acid injection (19AA-I). Glutamine is an important conditionally essential amino acid. Since glutamine is unstable in aqueous solution and when stored for a long time, and its solubility is very low (about 3g / L, 20°C), it is made into a dipeptide, i.e. alanyl glutamine, and added separately when administered intravenously. Its clinical representative drug is alanyl glutamine injection. In addition, there are dipeptide injections of glycyl glutamine and glycyl tyrosine. In order to ensure the stability of amino acids in compound amino acid injection products, amino acid preparations generally add sulfites (sodium pyrosulfite, sodium bisulfite) as antioxidants in the prescription. Sulfite has potential toxic risks, which are manifested in two aspects: inducing hypersensitivity reactions and damaging tissues and organs. Protein is a key substance for maintaining the survival of the body. Almost all clinical nutrition assessment methods involve the assessment of protein metabolism. Nitrogen balance can dynamically reflect the body's protein level and energy balance. When the body's nitrogen intake is greater than the excretion, it is a positive nitrogen balance, and when it is less than the excretion, it is a negative nitrogen balance. The human body has a regulatory effect on nitrogen balance to a certain extent. When the daily protein intake of normal adults increases or decreases, the decomposition rate and excretion of protein in the body will also increase or decrease accordingly. However, in certain disease states, such as pancreatitis, gastrointestinal resection, Cushing's syndrome, trauma, infection, renal dysfunction, burns, etc., negative nitrogen balance will be caused. Therefore, the body's demand for protein is different under normal conditions or different disease states. Compound amino acid injection is currently the main form of protein supply in parenteral nutrition. It fully meets the body's protein needs and rationally selects different formulas of amino acid injection, which is expected to achieve better nutritional treatment goals.The emergence and development of compound amino acid injection makes it possible to supplement amino acids intravenously, but as a drug, compound amino acid injection should ensure effectiveness and safety in clinical applications. In terms of effectiveness, the ratio of various amino acids for intravenous infusion should meet the needs of the body, especially for patients who are in special pathological and physiological conditions and cannot be given nutrition through the gastrointestinal tract. According to the metabolic characteristics of special populations, appropriate amino acid preparations and doses should be selected at the right time to play the nutritional therapeutic role that amino acid injection should have. In terms of safety, in clinical applications, we should not only pay attention to compatibility safety and avoid known drug interactions, but also pay attention to the adverse effects of antioxidants and other ingredients in compound amino acid injection on the drug itself and susceptible populations, clarify the corresponding quality standard range and the quality progress of compound amino acid injection preparations at home and abroad. In the future, with the continuous development of science and technology and pharmaceutical technology, we expect that people will be able to use safer and more effective compound amino acid injections. At the same time, with the continuous development of research in the fields of nutritional metabolism and clinical nutrition, we expect that people will also introduce more scientific and rigorous clinical application methods for compound amino acid injections.

[0030] The method of the present invention presents excellent technical effects in one or more aspects of the present invention, for example, it can quickly and accurately determine the content of specific impurities in the compound amino acid injection. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 : Chromatogram of the test solution of compound amino acid injection (18AA), in which the chromatographic peak with a retention time of about 9.2 min is the 2-sulfotryptophan peak.

[0032] Figure 2 : Chromatogram of compound amino acid injection (18AA) without sodium bisulfite, in which there is no chromatographic peak of 2-sulfotryptophan at a retention time of about 9.2 min.

[0033] Figure 3 : The chromatogram of the solution obtained by adding sodium bisulfite to the compound amino acid injection (18AA) without sodium bisulfite, in which the chromatographic peak of 2-sulfotryptophan is shown at a retention time of about 9.2 min. DETAILED DESCRIPTION

[0034] The present invention can be further described by the following examples, however, the scope of the present invention is not limited to the following examples. It will be appreciated by those skilled in the art that various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention. The present invention generally and / or specifically describes the materials and test methods used in the test. Although many materials and operating methods used to achieve the purpose of the present invention are well known in the art, the present invention is still described as detailed as possible herein. The following examples further illustrate the present invention, but are not intended to limit the present invention. Some compound amino acid injection samples used in the specific examples of the present invention, if not otherwise specified, are commercially available finished products, and are related to: compound amino acid (15) dipeptide (2) injection, compound amino acid injection (18AA), compound amino acid injection (18AA-I), compound amino acid injection (18AA-II), compound amino acid injection (18AA-III). If a self-prepared injection is mentioned, it is an injection or solution prepared by oneself according to the corresponding prescription.

[0035] Example 1: Preparation of 2-sulfotryptophan

[0036] 5 g of tryptophan and 5 g of sodium bisulfite were added to 50 ml of water to dissolve them, and the mixture was divided into ampoules and sealed, 5 ml per bottle, sterilized by hot pressing at 115 ° C for 15 min, and then placed at 40 ° C for 10 days, filtered, and chromatographically separated on an Innova! C18 preparative chromatographic column (30×250 mm, 5 μm, item number IX951530-0) with a water-acetonitrile (70:30) mixture as the mobile phase. The detection wavelength was 254 nm, and the eluted fraction of the 2-sulfotryptophan peak was intercepted (sodium bisulfite did not show a chromatographic peak, and two chromatographic peaks, small first and large later, were shown in the chromatogram. The large peak was tryptophan, and the small peak was the impurities produced). The solvent was evaporated, a small amount of water was added to the residue to dissolve it, and an appropriate amount of cyclohexane was added to form crystals, and the crystals were filtered out; recrystallized again with water-cyclohexane to obtain crystal A, which was identified as 2-sulfotryptophan by Example 2.

[0037] In addition, referring to the above method, except that sodium bisulfite was replaced by sodium pyrosulfite, the obtained crystal B was subjected to structural confirmation by the method of Example 2, and the result was the same as that of crystal A, indicating that the impurity obtained by using sodium pyrosulfite was also 2-sulfotryptophan.

[0038] Example 2: Structural Confirmation

[0039] In this Example 2, the structure of the crystal A obtained in Example 1 was confirmed.

[0040] 1.1 Structural formula, molecular formula, molecular weight

[0041] Through the determination in Example 2, it was finally determined that the crystal A was 2-sulfotryptophan, that is, a compound of the following formula I:

[0042] Structural formula:

[0043]

[0044] Molecular formula: C 11 H 12 N2O5S

[0045] Molecular weight: 284.29

[0046] 1.2 Mass spectrometry analysis

[0047] 1.2.1 ESI-MS mass spectrometry detection

[0048] Instrument model: Mass spectrometer QSTAR Elite LC / MS / MS System (CADM-YQ-014)

[0049] Ionization method: ESI-MS.

[0050] Testing basis: Chinese Pharmacopoeia 2015 Edition Part IV General Rules 0431 Mass Spectrometry

[0051] Determination results: A [M+H]+ molecular ion peak of m / z 285.1 can be observed in the ESI-MS spectrum, indicating that the relative molecular mass of this product is 284.1.

[0052] 1.2.2. TOF-MS high-resolution mass spectrometry detection

[0053] Test conditions: TOF MS ES(+) / (-)

[0054] Determination data: High-resolution mass spectrometry data of 2-sulfotryptophan. Mass-to-charge ratio assignments are detailed in Table 1 Mass spectrometry test data and assignments.

[0055] Table 1: Mass spectrometry test data and attribution

[0056] Mass-to-charge ratio (m / z) Relative abundance Molecular formula Peak attribution Remark 285.0536 100 <![CDATA[C 11 H 12 N2O5S]]> <![CDATA[[M+H] + ]]> Molecular ion peak of 2-sulfotryptophan

[0057] 1.2.3 Mass-to-charge ratio analysis

[0058] The molecular formula of 2-tryptophan bisulfite (abbreviated as impurity S) is C 11 H 12 The molecular weight of N2O5S calculated in Chemdraw software is 284.29, and the mass-to-nuclear ratio m / e is 284.05; the molecular ion peak [M+H] actually measured by ESI mass spectrometry is + m / z 285.1; the actual measured value of high resolution mass spectrometry is [M+H] +The mass-to-nuclear ratio (m / z) is 285.0536, and the molecular formula with the highest matching degree is C 11 H 13 N2O5S, so the molecular formula is determined to be C 11 H 12 N2O5S, which is consistent with the molecular formula of 2-tryptophan bisulfite.

[0059] Conclusion: The molecular weight of ESI mass spectrometry and high-resolution mass spectrometry is consistent with the value of impurity S calculated by Chemdraw software, and the elemental composition and molecular formula C are determined. 11 H 12 N2O5S is consistent with the identified structure.

[0060] 1.3. Nuclear magnetic resonance spectrum analysis

[0061] Instrument model: BRUKER AVANCEIII-400 NMR instrument

[0062] Solvent: CD3OD.

[0063] 1.3.1. Nuclear Magnetic Resonance Spectrum Hydrogen Spectrum

[0064] The following structures are chemical structures marked with corresponding atomic numbers for nuclear magnetic resonance spectrum analysis. Their attributions are detailed in Table 2 Chemical shifts and attributions of hydrogen atoms in nuclear magnetic resonance hydrogen spectrum analysis.

[0065]

[0066] Table 2: Chemical shift and attribution of hydrogen atoms analyzed by H NMR spectrum

[0067] Chemical shift (ppm) Number of protons Peak shape Attribution COSY-related coupling 3.545-3.601 1 dd 8 9-H, Self 3.677-3.727 1 dd 8 9-H, Self 4.220-4.250 1 m 9 8-H 7.055-7.092 1 m 5 6-H, 4-H 7.181-7.219 1 m 6 7-H, 5-H 7.396-7.416 1 d 7 6-H 7.594-7.614 1 d 4 5-H

[0068] The molecular formula of 2-sulfotryptophan is C 11 H 12 N2O5S has 12 hydrogens in its structure, 5 of which are active hydrogens. Since this product is only soluble in methanol and water but not in other deuterated reagents such as DMSO, when deuterated methanol is used for testing, the 5 active hydrogens cannot be seen, and only 7 hydrogen signals appear. The structure was confirmed based on the chemical shift value, integral ratio, coupled splitting, and combined with the COSY spectrum. The proton peaks of each group are analyzed and assigned as follows:

[0069] δ3.545-3.601ppm is a dd doublet peak with an integrated area of ​​1 hydrogen, which is a hydrogen signal in the 8-position methylene. It is coupled with the adjacent 9-H hydrogen and split by itself. The COSY spectrum shows that it has a mutual coupling relationship with 9-H and another hydrogen signal at its own 8-position.

[0070] δ3.677-3.727ppm is a dd doublet peak with an integrated area of ​​1 hydrogen, which is a hydrogen signal in the 8-position methylene. It is coupled with the adjacent 9-H hydrogen and split by its own coupling. The COSY spectrum shows that it has a mutual coupling relationship with 9-H and another hydrogen signal at its own 8-position.

[0071] δ4.220-4.250ppm is the m triplet peak, the integrated area is 1 hydrogen, which is the 9-position methine peak. The COSY spectrum shows that the 2 hydrogen signals at the 8-position are mutually coupled.

[0072] δ7.055-7.092ppm is the m triplet with an integrated area of ​​1 hydrogen, which is the hydrogen signal on the 5-position benzene ring. It is split into a triplet due to coupling at the 6- and 4-positions. The COSY spectrum shows a mutual coupling relationship with the 6- and 4-position hydrogen signals.

[0073] δ7.181-7.219ppm is the m triplet, with an integrated area of ​​1 hydrogen, which is the hydrogen signal on the 6-position benzene ring. It is split into a triplet due to coupling at the 7- and 5-positions. The COSY spectrum shows a mutual coupling relationship with the 7- and 5-position hydrogen signals.

[0074] δ7.396-7.416ppm is a doublet with an integrated area of ​​1 hydrogen, which is the hydrogen signal on the 7-position benzene ring. It is coupled with the 6-position hydrogen and splits into a doublet. The COSY spectrum shows that the 6-position hydrogen signal has a mutual coupling relationship with it.

[0075] δ7.594-7.614ppm is a doublet with an integrated area of ​​1 hydrogen, which is a hydrogen signal on the 4-position benzene ring. It is coupled to the 5-position hydrogen and splits into a doublet. The COSY spectrum shows that the 5-position hydrogen signal is mutually coupled with it. Conclusion: There are a total of 7 hydrogen signals in the hydrogen spectrum of the impurity reference substance. Since only deuterated methanol can be used, 5 active hydrogens are exchanged and cannot be seen. In addition, its structural type, coupling relationship and number are consistent with the structure of 2-sulfotryptophan.

[0076] 1.3.2. Analysis of C-NMR Spectra

[0077] The following structures are chemical structures marked with corresponding atom numbers for NMR spectrum analysis. The attribution is detailed in Table 3. NMR carbon spectrum, DEPT spectrum, HSQC, HMBC data and attribution

[0078]

[0079] Table 3: C NMR spectrum, DEPT spectrum, HSQC, HMBC data and attribution

[0080]

[0081]

[0082] The molecular formula of 2-tryptophan bisulfite is C 11 H 12 N2O5S, which has the same performance as the carbon spectrum, has 11 carbons in its structure, including 1 secondary carbon, 6 tertiary carbons, and 5 quaternary carbons. Combining the chemical shift values ​​of the C spectrum, the DEPT spectrum, and the HSQC spectrum, the analysis and attribution are as follows:

[0083] δ26.26ppm, DEPT spectrum suggests it is secondary carbon, HSQC spectrum shows that the 8-position hydrogen spectrum is coupled with it, so it can be inferred that this is the 8-position CH2 carbon atom.

[0084] δ54.81ppm, DEPT spectrum indicates that it is a tertiary carbon, which is the 9-position methine carbon signal. HSQC spectrum shows that the 9-position hydrogen spectrum has a coupling relationship, so it can be inferred that this carbon is the 9-position CH carbon atom.

[0085] δ107.60ppm, DEPT spectrum suggests quaternary carbon, HSQC spectrum shows no relevant peaks, and the peak position of the carbon spectrum can be inferred to be the 3-position carbon atom.

[0086] δ113.25ppm, DEPT spectrum indicates that it is a tertiary carbon, which is the signal of the 7-position methine carbon. HSQC spectrum shows that the 7-position hydrogen spectrum has a coupling relationship, so it can be inferred that this carbon is the 7-position CH carbon atom.

[0087] δ120.31ppm, DEPT spectrum indicates that it is a tertiary carbon, which is the 4-position methine carbon signal. HSQC spectrum shows that the 4-position hydrogen spectrum has a coupling relationship, so it can be inferred that this carbon is the 4-position CH carbon atom.

[0088] δ121.32ppm, DEPT spectrum indicates that it is a tertiary carbon, which is the 5-position methine carbon signal. HSQC spectrum shows that the 5-position hydrogen spectrum has a coupling relationship, so it can be inferred that this carbon is the 5-position CH carbon atom.

[0089] δ125.03ppm, DEPT spectrum indicates that it is a tertiary carbon, which is the 6-position methine carbon signal. HSQC spectrum shows that the 6-position hydrogen spectrum has a coupling relationship, so it can be inferred that this carbon is the 6-position CH carbon atom.

[0090] 1.3.3 HMBC spectrum analysis

[0091] The five quaternary carbon signals in the structure have no direct correlation with CH. The confirmation based on the chemical shift values ​​and HMBC spectrum is shown in Table 3. The data and attribution of the NMR carbon spectrum, DEPT spectrum, HSQC, and HMBC spectrum are as follows:

[0092] δ107.60ppm, DEPT spectrum suggests quaternary carbon, HMBC spectrum shows that this group of carbon signals are related to hydrogen at positions 4, 8, and 9. Combined with the chemical shift value of the carbon spectrum, it can be reasonably attributed to the quaternary carbon signal at position 3.

[0093] δ128.16ppm, DEPT spectrum suggests quaternary carbon, HMBC spectrum shows that this group of carbon signals is related to hydrogen at positions 5, 7, and 8. Combined with the chemical shift value of the carbon spectrum, it can be reasonably attributed to the quaternary carbon signal at position 3a.

[0094] δ136.08ppm, DEPT spectrum suggests quaternary carbon, HMBC spectrum shows that this group of carbon signals is related to hydrogen at positions 4 and 6. Combined with the chemical shift value of the carbon spectrum, it can be reasonably attributed to the quaternary carbon signal at position 7a.

[0095] δ138.12ppm, DEPT spectrum suggests quaternary carbon, HMBC spectrum shows that this group of carbon signals is related to hydrogen at position 8, and combined with the chemical shift value of the carbon spectrum, it can be reasonably attributed to the quaternary carbon signal at position 2.

[0096] δ172.5ppm, DEPT spectrum suggests quaternary carbon, HMBC spectrum shows that this group of carbon signals is related to hydrogen at positions 8 and 9. Combined with the chemical shift value of the carbon spectrum, it can be reasonably attributed to the quaternary carbon signal at position 10.

[0097] Conclusion: All carbon spectrum signals have been reasonably assigned, and the carbon type has been confirmed by DEPT and HMBC spectra. In summary, the carbon and hydrogen assignments of sample crystal A confirm that its structure is 2-sulfotryptophan.

[0098] When the tryptophan raw material used in Example 1 was measured using the method of the present invention for measuring related substances in compound amino acid injection, 2-sulfotryptophan was not detected, which was below the detection limit, indicating that crystal A was generated by the reaction of tryptophan with sodium bisulfite or sodium pyrosulfite.

[0099] According to the preparation process of Crystal A in Example 1, it can be concluded that it is generated by the sulfonation reaction of tryptophan and sulfite, and the reaction formula is as follows:

[0100]

[0101] According to the context of the present invention, 2-sulfotryptophan is a specific impurity generated by the reaction between tryptophan in the compound amino acid injection and the antioxidant sodium bisulfite or sodium pyrosulfite, and does not exist in the tryptophan raw material. Currently, there is no effective method for detecting this impurity in the art. In order to effectively control product quality and ensure the safety and reliability of the product during the shelf life, it is quite necessary to establish a rapid, simple, sensitive and stable method to control the content of 2-sulfotryptophan in the compound amino acid injection.

[0102] Example 3: Qualitative and quantitative determination of 2-sulfotryptophan in compound amino acid injection

[0103] The purpose of this embodiment is to provide a method for qualitative and quantitative determination of 2-sulfotryptophan in a compound amino acid injection, which is expected to be rapid, simple, sensitive and stable. The method comprises the following steps:

[0104] 1. Instrument: High performance liquid chromatography

[0105] 2. Chromatographic column: Octadecylsilane bonded silica gel (C18 column, size 4.6×150mm, 3.5μm, this example uses Waters SunFire brand chromatographic column, other brands of chromatographic columns with the same performance can also be used) as filler

[0106] 3. Chromatographic conditions:

[0107] Use ammonium sulfate buffer (take 5g of ammonium sulfate, 5.25g of sodium heptane sulfonate, add 900ml of water to dissolve, adjust pH to 1.5 with hydrochloric acid, add water to 1000ml)-acetonitrile (97:3) as mobile phase A, acetonitrile as mobile phase B, injection volume 25μl, column temperature 40℃, gradient elution according to Table 1. Detection wavelength 220nm.

[0108] Table 1: Gradient elution table

[0109] time B% 0 0 18 0 27 45 32 0 53 0

[0110] 4. Preparation of the test solution: accurately measure 2.5 ml of compound amino acid injection and place it in a 5 ml volumetric bottle, accurately add 0.2 ml of ethylenediamine and 2 ml of acetone, mix well, add acetone to the scale, vortex mix for 15 minutes and filter, accurately measure 2 ml of the filtrate, place it in a 10 ml volumetric bottle, and dilute it to the scale with ultrapure water (prepared by a pure water machine, resistivity ≥ 18.2 MΩ) as the test solution. [If the concentration of the impurity 2-sulfotryptophan in the test solution is too high, continue to dilute it with water]

[0111] 5. Preparation of reference solution: Take an appropriate amount of 2-sulfotryptophan obtained in Example 1 (crystal A, measured by the method under the chromatographic conditions of Example 3, the chromatographic purity measured at wavelengths of 220 nm, 254 nm, and 280 nm is 99.87%, 99.85%, and 99.94%, respectively) and add ultrapure water to prepare a series of reference solutions with concentrations of 0.051, 0.103, 0.514, 1.028, 1.542, and 2.056 μg / ml.

[0112] 6. Methodological validation:

[0113] 6.1 Linear

[0114] Preparation of linear solution: Accurately measure 25 μl of each series of 2-sulfotryptophan reference solution and inject it into the liquid chromatograph to record the chromatogram. Perform linear regression with concentration as the horizontal axis and peak area as the vertical axis. For detailed data, see Table 2 Linearity test results.

[0115] Table 2: 2-sulfotryptophan linearity test results

[0116] Linear solution 2-sulfotryptophan concentration (μg / ml) 2-sulfotryptophan peak area 1 0.051 0.0453 2 0.103 0.0906 3 0.514 0.4376 4 1.028 0.8735 5 1.542 1.3351 6 2.056 1.7672

[0117] Test results: 2-sulfotryptophan is in the range of 0.051 μg / ml to 2.056 μg / ml, the linear equation of 2-sulfotryptophan concentration and peak area is y=0.8606x-0.0012, and the correlation coefficient is r=0.9999; it meets the test requirements.

[0118] 6.2 Accuracy

[0119] Accuracy was examined by recovery rate.

[0120] Accurately measure 2.5 ml of compound amino acid injection (18AA) (batch number JM2000157) and place it in a 5 ml volumetric bottle, accurately add 0.2 ml of ethylenediamine and 2 ml of acetone, mix well, add acetone to the scale, vortex mix for 15 minutes and filter, accurately measure 2 ml of the filtrate, place it in a 10 ml volumetric bottle, add 24 μl, 30 μl, and 36 μl of the stock solution for linear test (2-sulfotryptophan content 0.1028 μg / ml), (n=3×3), dilute to the scale with water, shake well, inject samples respectively, record chromatograms, and calculate the recovery rate respectively according to the external standard method. The specific results are shown in Table 3. Sample recovery test results.

[0121] Table 3: 2-sulfotryptophan recovery test results

[0122]

[0123] Conclusion: The recovery rate of 2-sulfotryptophan was in the range of 99.32% to 102.04%, with an average recovery rate of 101.2% and an RSD of 0.8%, which met the test requirements.

[0124] 6.3 Precision

[0125] Precision is examined by repeatability test. Take the sample of batch number JM2000157, prepare 6 samples of sample solution according to the item "4. Preparation of test solution", and use them as repeatability sample solution for determination to examine the precision of the method. The results are shown in Table 4 Repeatability test results.

[0126] Table 4: 2-sulfotryptophan repeatability test results

[0127]

[0128]

[0129] 6.4 Limit of Quantitation and Limit of Detection

[0130] Preparation of 2-sulfotryptophan quantification limit and detection limit solutions: Take linear test solution 1 (2-sulfotryptophan concentration 0.051 μg / ml), dilute it step by step and measure it until the signal-to-noise ratio S / N is 10:1 as the quantification limit and the S / N is 3:1 as the detection limit.

[0131] Conclusion: The quantification limit of 2-sulfotryptophan is 0.026μg / ml and the detection limit is 0.013μg / ml.

[0132] 6.5 Solution stability

[0133] The test solution prepared from the sample of batch number JM2000157 was placed at room temperature, and the 2-sulfotryptophan content was measured at 0 hour, 4 hours, 8 hours, 12 hours, and 24 hours, respectively. The stability of the solution was investigated by the relative standard deviation of the 2-sulfotryptophan peak area.

[0134] The results are shown in Table 5 for stability test results.

[0135] Table 5: 2-sulfotryptophan stability test results

[0136]

[0137] Conclusion: 2-sulfotryptophan is stable at room temperature for 24 hours and meets the test requirements.

[0138] 6.6. System suitability test of HPLC method: add appropriate amount of reference substance to compound amino acid injection to a concentration of 1 μg / ml to obtain system suitability test solution, inject reference substance solution and system suitability test solution into liquid chromatograph respectively, determine the retention time of 2-sulfotryptophan by the chromatogram of reference substance solution, and the separation degree between 2-sulfotryptophan and its adjacent chromatographic peak in the chromatogram of system suitability test solution should be greater than 5.0. The test results are all greater than 8.0.

[0139] 6.7. Determination of the content of 2-sulfotryptophan impurity in injection: Accurately measure the test solution and the reference solution (select the reference solution with a concentration equivalent to that of 2-sulfotryptophan in the test solution), inject them into the chromatograph respectively, record the chromatogram, calculate the content of 2-sulfotryptophan impurity in the test solution by the peak area according to the external standard method, and calculate the content of 2-sulfotryptophan impurity in the compound amino acid injection according to the dilution multiple of the prepared solution.

[0140] In the method of Example 3, the chromatogram of the test sample of compound amino acid injection (18AA) is as follows: Figure 1 As shown in the figure, the chromatographic peak with a retention time of about 9.2 minutes is the 2-sulfotryptophan peak.

[0141] In addition, using the chromatographic conditions of Example 3, the crystals A and B obtained in Example 1 were measured, and the retention time of the main peaks of the two samples was about 9.2 min, and the chromatographic purities calculated by the hundred product normalization method were greater than 99%.

[0142] Example 31: The accuracy test, i.e., the recovery test, was performed with reference to the method of "6.2, Accuracy" in Example 3 above, except that acetone was not added when the test solution was prepared. As a result, the average recoveries of the three concentration levels of low, medium, and high were 87.32%, 91.61%, and 88.76%, respectively; the accuracy test, i.e., the recovery test, was performed with reference to the method of "6.2, Accuracy" in Example 3 above, except that ethylenediamine was not added when the test solution was prepared. As a result, the average recoveries of the three concentration levels of low, medium, and high were 92.47%, 89.33%, and 90.38%, respectively; the accuracy test, i.e., the recovery test, was performed with reference to the method of "6.2, Accuracy" in Example 3 above, except that ethylenediamine was not added when the test solution was prepared. As a result, the average recoveries of the three concentration levels of low, medium, and high were 92.47%, 89.33%, and 90.38%, respectively. The operation of the test solution was changed to "precisely measure 1 ml of compound amino acid injection (18AA), place it in a 10 ml volumetric flask, add 24 μl, 30 μl, and 36 μl of stock solution for linear test (2-sulfotryptophan content 0.1028 μg / ml), (n=3×3), dilute to the scale with water, shake well, and inject respectively", that is, neither acetone nor ethylenediamine was added. As a result, the average recoveries of the three concentration levels of low, medium, and high were 88.39%, 87.46%, and 89.27%, respectively; the RSDs of these average recovery results of this Example 31 were all in the range of 0.6% to 1.4%; the results of this Example 31 show that the recovery rate is obviously unacceptable when these changed solution preparation methods are used as impurity content determination. Example 32: Referring to the formula of the compound amino acid injection (18AA) recorded in the Chinese Pharmacopoeia, but without adding sodium bisulfite, the solution was prepared according to the conventional method and then packaged into ampoules and sealed. Each bottle had 5 ml, and was sterilized by autoclave at 115°C for 15 minutes, and then placed at 40°C for 10 days to obtain a compound amino acid injection (18AA) without sodium bisulfite. The chromatogram was shown in the following figure. Figure 2 As shown, there is no chromatographic peak at a retention time of about 9.2 min in the display diagram, indicating that the injection solution without the addition of sodium bisulfite will not have the impurity 2-sulfotryptophan peak.

[0143] Example 33: Sodium bisulfite (to a concentration of 0.5 mg / ml) was added to the sodium bisulfite-free compound amino acid injection (18AA) prepared in Example 32 above and sterilized and treated at 40°C. After adding sodium bisulfite, the mixture was divided into ampoules and sealed, sterilized by hot pressing at 115°C for 15 min, and then placed at 40°C for 10 days to obtain a sodium bisulfite-added solution. The solution was measured using the method of Example 3, and its chromatogram was as follows: Figure 3As shown, a chromatographic peak of the impurity 2-sulfotryptophan appears at a retention time of about 9.2 min, indicating that after the addition of sodium bisulfite, a typical impurity 2-sulfotryptophan peak resulting from the reaction of tryptophan with sulfite appears.

[0144] Example 34: Referring to the formula of the compound amino acid injection (18AA) recorded in the Chinese Pharmacopoeia, but without adding tryptophan, the solution was prepared according to the conventional method and then packaged into ampoules and sealed, 5 ml per bottle, and sterilized by hot pressing at 115°C for 15 min, followed by storage at 40°C for 10 days to obtain a tryptophan-free compound amino acid injection (18AA). The result showed that there was no chromatographic peak at a retention time of about 9.2 min in the chromatogram (not provided), indicating that the injection without adding tryptophan would not have the impurity 2-sulfotryptophan peak.

[0145] Example 4: Determination of impurity content in compound amino acid injection

[0146] The high performance liquid chromatography method of Example 3 of the present invention is carried out according to the specifications in the General Rules 0512 of the Fourth Part of the 2020 Edition of the Chinese Pharmacopoeia. The method can be briefly summarized as follows:

[0147] Chromatographic conditions: using octadecylsilane bonded silica gel as filler (for example, the specification of the chromatographic column used is C18 column, 4.6×150mm, 3.5μm, this example uses Waters SunFire brand chromatographic column, other brands of chromatographic columns with the same performance can also be used), using ammonium sulfate buffer (take 5g of ammonium sulfate, 5.25g of sodium heptane sulfonate, add 900ml of water to dissolve, adjust the pH to 1.5 with hydrochloric acid, and add water to 1000ml)-acetonitrile (97:3) as mobile phase A, using acetonitrile as mobile phase B, gradient elution according to the table below, injection volume 25μl, column temperature 40°C, detection wavelength 220nm;

[0148] time B% 0 0 18 0 27 45 32 0 53 0

[0149] Reference solution: accurately weigh an appropriate amount of 2-sulfotryptophan reference substance, dissolve it in water and quantitatively dilute it to make a solution with a concentration of 0.05-0.2 μg / ml as the reference solution; (the concentration of the reference solution can be appropriately adjusted according to the impurity 2-sulfotryptophan in different test samples, so that the concentration of the reference solution is within a comparable concentration range with the concentration of the impurity in the test solution); Test solution: accurately measure 2.5 ml of compound amino acid injection solution and place it in a 5 ml volumetric flask, accurately add 0.2 ml of ethylenediamine and 2 ml of acetone, mix well, add acetone to the scale, and vortex. After mixing for 15 minutes, filter, accurately measure 2 ml of the filtrate, place it in a 10 ml volumetric flask, and dilute it to the mark with ultrapure water as the test solution; System suitability test: add an appropriate amount of reference substance to the compound amino acid injection to a concentration of 1 μg / ml to obtain a system suitability test solution, inject the reference substance solution and the system suitability test solution into a liquid chromatograph, respectively, and determine the retention time of 2-sulfotryptophan through the chromatogram of the reference substance solution. The separation between 2-sulfotryptophan and its adjacent chromatographic peaks in the chromatogram of the system suitability test solution should be greater than 5.0;

[0150] Determination method: Accurately measure the test solution and the reference solution, inject them into the chromatograph respectively, record the chromatogram, calculate the content of the impurity 2-sulfotryptophan in the test solution by the peak area according to the external standard method, and calculate the content of the impurity 2-sulfotryptophan in the compound amino acid injection according to the dilution multiple of the prepared solution.

[0151] Using the HPLC method summarized above, one batch each of five injections, namely, compound amino acid (15) dipeptide (2) injection, compound amino acid injection (18AA), compound amino acid injection (18AA-I), compound amino acid injection (18AA-II), and compound amino acid injection (18AA-III) from commercial sources, were taken to determine the content of the impurity 2-sulfotryptophan. The results were 3.36 μg / ml, 2.72 μg / ml, 5.61 μg / ml, 4.31 μg / ml, and 6.27 μg / ml, respectively. In addition, after the above five injections were placed at 40°C for one month, the content of the impurity 2-sulfotryptophan therein was measured. The content of the impurity in each sample was compared with the result at 0 month to calculate the increase percentage of the impurity. The increase percentage of the impurity 2-sulfotryptophan in the five injections was all within the range of 67 to 94%. For example, the increase percentage of the impurity 2-sulfotryptophan in the compound amino acid injection (18AA) was 84.2%.

[0152] It is obvious to those skilled in the art that the present application is not limited to the details of the above exemplary embodiments, and that the present application can be implemented in other specific forms without departing from the spirit or essential features of the present application. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive, and the scope of the present application is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present application.

Claims

1. A method for checking related substances in a compound amino acid injection, wherein the method uses high performance liquid chromatography to determine the content of 2-sulfotryptophan, an impurity in the injection, wherein the compound amino acid injection contains tryptophan and sodium bisulfite or sodium pyrosulfite, and the method comprises the following operations: It is carried out according to the specifications of high performance liquid chromatography in the general rules 0512 of the fourth volume of the 2020 edition of the Chinese Pharmacopoeia; Chromatographic conditions: The chromatographic column is filled with octadecylsilane bonded silica gel, and the column specifications are 4.6×150mm, 3.5μm; Use ammonium sulfate buffer-acetonitrile with a volume ratio of 97:3 as mobile phase A and acetonitrile as mobile phase B, and follow the gradient elution as shown in the table below: ; Injection volume 25 μl, column temperature 40 °C, detection wavelength 220 nm; The preparation method of ammonium sulfate buffer is as follows: take 5g of ammonium sulfate and 5.25g of sodium heptane sulfonate, add 900ml of water to dissolve, adjust the pH to 1.5 with hydrochloric acid, and add water to 1000ml; Reference solution: Accurately weigh an appropriate amount of 2-sulfotryptophan reference substance, dissolve it in water and quantitatively dilute it to make a solution with a concentration of 0.05~0.2μg / ml as the reference solution; Test solution: accurately measure 2.5 ml of compound amino acid injection and place it in a 5 ml volumetric flask, accurately add 0.2 ml of ethylenediamine and 2 ml of acetone, mix well, add acetone to the scale, vortex mix for 15 minutes and filter, accurately measure 2 ml of the filtrate, place it in a 10 ml volumetric flask, and dilute to the scale with ultrapure water as the test solution; System suitability test: add an appropriate amount of 2-sulfotryptophan reference substance to the compound amino acid injection to a concentration of 1 μg / ml to obtain a system suitability test solution, inject the reference substance solution and the system suitability test solution into a liquid chromatograph respectively, and determine the retention time of 2-sulfotryptophan by the chromatogram of the reference substance solution. The separation between 2-sulfotryptophan and its adjacent chromatographic peaks in the chromatogram of the system suitability test solution should be greater than 5.0; Determination method: Accurately measure the test solution and the reference solution, inject them into the chromatograph respectively, record the chromatogram, calculate the content of the impurity 2-sulfotryptophan in the test solution by the peak area according to the external standard method, and calculate the content of the impurity 2-sulfotryptophan in the compound amino acid injection according to the dilution multiple of the prepared solution.

2. The method according to claim 1, wherein the correlation coefficient of the linear equation of 2-sulfotryptophan in the concentration range of 0.05 μg / ml to 2.0 μg / ml is r>0.

999.

3. The method according to claim 1, wherein the method recovery of 2-sulfotryptophan is greater than 95%.

4. The method according to claim 1, wherein the method recovery of 2-sulfotryptophan is greater than 98%.

5. according to the method for claim 1, wherein the method recovery of 2-sulfotryptophan is between 98% and 102%.

6. The method according to claim 1, wherein the detection limit of 2-sulfotryptophan is less than 0.02 μg / ml.

7. according to the method for claim 1, wherein the RSD of the 2-sulfotryptophan content determination result of the prepared test solution at room temperature for 0 to 24 hours is less than 1%.

8. According to the method of claim 1, the compound amino acid injection is selected from: compound amino acid 15 dipeptide 2 injection, compound amino acid injection 18AA, compound amino acid injection 18AA-I, compound amino acid injection 18AA-II, and compound amino acid injection 18AA-III.